Research With BCMA-Targeted Agents, Venetoclax Appears Promising in Myeloma

Ellie Leick
Published: Monday, Mar 09, 2020
Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health Perlmutter Cancer Center

Gareth J. Morgan, MD, PhD

BCMA-targeted therapies, including CAR T-cell therapy, antibody-drug conjugates (ADCs), and bispecific T-cell engagers are shifting the multiple myeloma paradigm to create longer remission times and improve quality of life (QoL) for patients, explained Gareth J. Morgan, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication